AES with Cancer

Method of production of navigability a concentrate for making Mr infusion vial. Pharmacotherapeutic group: L01HS06 - Antineoplastic agents. Indications for use drugs: metastatic breast cancer with tumor hyperexpression HER2 - as monotherapy if the patient has already received one or more schemes of chemotherapy on metastatic stage disease in combination with paclitaxel, if the patient navigability not received chemotherapy on metastatic stage of disease. Method of production of drugs: lyophilized powder for preparation of concentrate for infusion of 150 mg to 440 mg in Flac. The main pharmaco-therapeutic effect: a monoclonal himerychni / t mouse / human, that specifically bind to transmembranym a / g SD20, and agriculture navigability located on pre-B lymphocytes and mature B-lymphocytes, but not on stovburovyhyh hematopoietic cells, pro- B-cells, navigability cells and plasma of healthy cells of other tissues, is expressed in more than 95% of B-cell lymphomas nehodzhkinskyh, after binding and / t internalizuyetsya SV20 is not removed from the membrane into the environment. trastuzumabom klitynnooposeredkovana caused cytotoxicity (AZKOTS) no effect on cancer cells, which hiperekspresuyut HER2, compared to cells in which HER2 is no hyperexpression. Pharmacotherapeutic group: L01XC03 - antitumor agents. Side effects and complications in the use of drugs: abdominal pain, diarrhea, nausea, vomiting, asthenia, chest pain, fever, chills, backache, flu-like s-m, infection, pain in the neck, malaise, AR, vasodilatation, tachycardia, hypotension, heart failure, cardiomyopathy, palpitation, anorexia, constipation, indigestion, leukopenia, edema, bone pain, anxiety, depression, dizziness, drowsiness, insomnia, paresthesia, hypertension, neuropathy, navigability cough, dyspnea, nasal bleeding, pathology of the lungs, pleural effusion, pharyngitis, rhinitis, sinusitis, cystitis, urethritis, itching, sweating, nail lesions, dry skin, hair loss, acne, makulo-papular rash, in the first infusion often chills, fever and may kupiruvatysya by with analgesics or type of refrigerant meperydynu or paracetamol, or antihistamines, such dyfenhidraminu; iInodi infusion reaction to a drug, that appears dyspnea, hypotension, appearance rattle in the lungs, bronchospasm, tachycardia, decrease in oxygen saturation and respiratory distress with-IOM can be severe and, in rare cases lead to fatal outcome, CH, shortness of breath, ortopnoe, increased Headache lung edema, gallop and three-term reduction of ejection fraction, hematotoksychnist, hepatotoksychnosti phenomenon accompanied the progression of metastatic liver damage. Indications for use of drugs: Non-Hodgkin's lymph - recurrent or resistant to chemotherapy of B-cells, SV20-positive Non-Hodgkin's lymphoma of low degree of malignancy or follicular, SV20-positive diffusion in velykoklitynni-Hodgkin's Lymphomas in combination with chemotherapy scheme Snoro; follicular lymphoma FE-IV stage, chemotherapy-resistant or recurrent (second or subsequent relapse after chemotherapy), previously untreated follicular lymphoma stage III-IV in combination with chemotherapy Suryo, supportive therapy follicular lymphomas after receiving responses Nia induction therapy of RA. N zoster); violation lacrimation, conjunctivitis, breach of taste sensations. Contraindications to the use of drugs: hypersensitivity to the drug, CNS metastatic lesions, pregnancy, lactation, infancy, renal navigability hepatic failure. mh/10 100 ml, 500 ml mh/50. Preparations of drugs: concentrate for making Mr 100 mg / 4 ml, 400 ml mh/16.